PRKACB Attenuates Chondrocyte Loss and Inflammation in Osteoarthritis
Immunity, Inflammation and Disease · 2026-02 · 14 (2)
DOI: 10.1002/iid3.70342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 12.02.2026. Verfasst von Weidan Xiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Bone Disease Clinic, The Affiliated Hospital of Wuhan Sports University, Wuhan, Hubei Province, China. Hauptthemen laut MEDLINE: Chondrocytes, Osteoarthritis, Inflammation, Cyclic AMP-Dependent Protein Kinase Catalytic Subunits. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shizhen Talent Program of Hubei Province for Scientific Researc.
Abstract (Originalsprache)
Background
Previous work revealed that protein kinase cAMP‐dependent catalytic β (PRKACB) may play a crucial role in osteoarthritis (OA) development. However, the mechanism by which PRKACB plays a role in OA still needs to be further investigated. Our aim was to explore the mechanism of PRKACB in a human chondrocyte inflammatory injury model.
Methods
Human CHON‐001 chondrocytes were treated with 10 ng/mL IL‐1β for 12 h to establish an in vitro model of chondrocyte inflammatory injury. Cell viability was determined by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assay. Flow cytometry (FCM) was conducted to assess apoptosis. Western blot assays were carried out to measure cleaved caspase‐3, caspase‐3, PRKACB, collagen II, aggrecan, phosphorated protein kinase A (p‐PKA), PKA, cAMP response element‐binding protein (CREB) and p‐CREB protein expression levels. Reverse transcription quantitative polymerase chain reaction (RT‐qPCR) assay was used to measure PRKACB gene expression. Interleukin 6 (IL‐6), IL‐1β, and tumor necrosis factor alpha (TNF‐α) levels were measured by enzyme‐linked immunosorbent assay (ELISA).
Results
PRKACB expression was decreased in IL‐1β‐treated CHON‐001 cells. Transfection of a PRKACB plasmid increased PRKACB expression in CHON‐001 cells. IL‐1β significantly inhibited CHON‐001 cell viability; induced apoptosis; increased cleaved caspase‐3 expression and the cleaved caspase‐3/caspase‐3 ratio; promoted TNF‐α, IL‐6 and IL‐8 secretion; and decreased the expression levels of collagen II and aggrecan. However, these effects could be suppressed by the PRKACB plasmid. Moreover, we also found that PRKACB activated the PKA/CREB signaling pathway. H89 (a PKA inhibitor) distinctly reversed the effect of PRKACB on IL‐1β‐induced CHON‐001 cells.
Conclusion
PRKACB can increase cell viability and reduce inflammation by activating the PKA/CREB signaling pathway, and PRKACB is a novel target for OA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Bone Disease Clinic, The Affiliated Hospital of Wuhan Sports University, Wuhan, Hubei Province, China.
- Department of Rehabilitation Medicine, The Affiliated Hospital of Wuhan Sports University, Wuhan, Hubei Province, China.
ORCID-Profile: Qijuan Zhang
Förderung
- Shizhen Talent Program of Hubei Province for Scientific Researc
Zitieren
APA
Xiao, W., Liu, Z., & Zhang, Q. (2026). PRKACB Attenuates Chondrocyte Loss and Inflammation in Osteoarthritis. Immunity, Inflammation and Disease, 14(2). https://doi.org/10.1002/iid3.70342
Vancouver
Xiao W, Liu Z, Zhang Q. PRKACB Attenuates Chondrocyte Loss and Inflammation in Osteoarthritis. Immunity, Inflammation and Disease. 2026;14(2). doi:10.1002/iid3.70342
BibTeX
@article{Xiao2026,
author = {Xiao, Weidan and Liu, Zhengmao and Zhang, Qijuan},
title = {PRKACB Attenuates Chondrocyte Loss and Inflammation in Osteoarthritis},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/iid3.70342}
}
EUVIMED